Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
The company has reported total income of Rs.14759 crores during the 9 months period ended December 31, 2020.
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
Analysts expect modest revenue growth but pressure on profitability in the March quarter
Company to launch product after the expiry of semaglutide patent in India
His career spans notable tenures at Syngene International Limited, Cipla, Nestlé, and Bharat Petroleum Corporation Limited
She has held senior positions at Coca-Cola in China and PepsiCo in India
Anushree has been with Abbott since 2021 and currently serving as Head of Strategy and Portfolio
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
Subscribe To Our Newsletter & Stay Updated
